AVLN NASDAQ
Avalyn Pharma Inc. Common Stock
1W: +4.9%
1M: -8.8%
3M: -8.1%
YTD: -12.4%
$25.83
-1.31 (-4.83%)
Weekly Expected Move ±9.0%
$21
$24
$26
$28
$31
Credit Risk of going bust: not rated Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range22.24-40.17
Volume961,285
Avg Volume310,560
Beta-1.13
Dividend—
Analyst Ratings
Company Info
CEOLyn Baranowski
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-30
Websiteavalynpharma.com
105 W First St. Boston
Boston, MA 02127
US
Boston, MA 02127
US
1-206-707-0340
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Latest News
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Recent Insider Trades
No insider trades found